To further investigate the potential impact of high PD-L1 expression or high TMB on the tumor signaling pathways in NSCLC patients with EGFR mutations, we conducted a tumor signaling pathway mutation analysis (pathways and related genes referenced in Table S2 in the previous study [17]). This evidence concerns the gene CD274 and neoplasm.